Clinical pharmacokinetics and pharmacodynamics of G3139 (Genta Incorporated) antisense oligonucleotide targeting BCL-2.

被引：0
|
作者：
Fingert, HJ [1 ]
Klem, RE [1 ]
机构：
[1] Genta Inc, Lexington, MA USA
来源：
CLINICAL CANCER RESEARCH | 1999年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
585
引用
收藏
页码：3847S / 3848S
页数：2
相关论文
共 50 条
  • [21] Evaluation of Pharmacokinetics and Metabolism of Phosphorothioate Antisense Oligonucleotide G3139 in Rat by Capillary Electrophoresis with Laser-Induced Fluorescence
    Ban, Eunmi
    Kwon, Haejin
    Song, Eun Joo
    NUCLEIC ACID THERAPEUTICS, 2021, 31 (04) : 316 - 320
  • [22] Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
    Morris, MJ
    Tong, WP
    Cordon-Cardo, C
    Drobnjak, M
    Kelly, WK
    Slovin, SF
    Terry, KL
    Siedlecki, K
    Swanson, P
    Rafi, M
    DiPaola, RS
    Rosen, N
    Scher, HI
    CLINICAL CANCER RESEARCH, 2002, 8 (03) : 679 - 683
  • [23] Oblimersen sodium (G3139 bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: A targeted approach to enhance apoptosis
    Frankel, SR
    SEMINARS IN ONCOLOGY, 2003, 30 (02) : 300 - 304
  • [24] Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice
    Wacheck, V
    Krepler, C
    Strommer, S
    Heere-Ress, E
    Klem, R
    Pehamberger, H
    Eichler, HG
    Jansen, B
    ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 2002, 12 (06): : 359 - 367
  • [25] Phase I trial of Genasense™ (G3139, GENTA, INC.), a BCL-2 antisense (AS), in refractory (REF) or relapsed (REL) acute leukemia (AL).
    Marcucci, G
    Bloomfield, CD
    Balcerzak, SP
    Kourlas, PJ
    Stanley, HR
    Fingert, H
    Maghraby, EA
    Lucas, D
    Chen, KK
    Byrd, JC
    Kraut, EH
    Grever, MR
    Caligiuri, MA
    BLOOD, 2000, 96 (11) : 119A - 119A
  • [26] G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD-refractory myeloma.
    van de Donk, NWCJ
    de Weerdt, O
    Veth, G
    Eurelings, M
    van Stralen, E
    Frankel, SR
    Hagenbeek, A
    Bloem, AC
    Lokhorst, HM
    BLOOD, 2003, 102 (11) : 690A - 690A
  • [27] Efficient delivery of the Bcl-2 antisense oligonucleotide G3139 via nucleus-targeted aCD33-NKSN nanoparticles
    Yan, Chengyun
    Gu, Jiwei
    Zhang, Yuan
    Ma, Kailun
    Lee, Robert J.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 625
  • [28] Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature
    E M Anderson
    P Miller
    D Ilsley
    W Marshall
    A Khvorova
    C A Stein
    L Benimetskaya
    Cancer Gene Therapy, 2006, 13 : 406 - 414
  • [29] Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature
    Anderson, EM
    Miller, P
    Ilsley, D
    Marshall, W
    Khvorova, A
    Stein, CA
    Benimetskaya, L
    CANCER GENE THERAPY, 2006, 13 (04) : 406 - 414
  • [30] Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
    Rudin, CM
    Kozloff, M
    Hoffman, PC
    Edelman, MJ
    Karnauskas, R
    Tomek, R
    Szeto, L
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1110 - 1117
12345